HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are key drugs of highly active antiretroviral therapy (HAART) in the clinical management of AIDS/HIV-1 infection. Our recent studies showed that indolylarylsulfones (IASs) bearing a cyclic moiety at the 2-carboxamide nitrogen linked through a short spacer group were endowed with potent antiretroviral activity. Based on the results previously obtained, we aimed to expand the SAR studies by the introduction of new aryl or heteroaryl portions to the indole nucleus. Interestingly, for the first time IASs endowed with asymmetric centre have shown significant differences in term of antiretroviral potency. In particular, the R-enantiomer proved to be exceptionally potent and uniformly superior to the S-enantiomer against the whole viral panel. Docking studies showed that the methyl group of the R-enantiomer (Figure 1) pointed toward the cleft created by the K103N mutation, differently from the corresponding group of (S) counterpart. By calculating the solvent accessible surface, we observed that the exposed area of the RT in complex with S-enantiomer was larger than the area of the (R) complex

Famiglini, V., La Regina, G., Coluccia, A., Masci, D., Roger, B., José A., E., Emmanuele, C., Giovanni, M., Drug design and synthesis of new indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors, Abstract de <<30th International Conference on Antiviral Research>>, (Atlanta, GA, USA, 21-25 May 2017 ), N/A, Atlanta (Georgia), USA 2017:2017 87-87 [http://hdl.handle.net/10807/195406]

Drug design and synthesis of new indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors

La Regina, Giuseppe;Masci, Domiziana;
2017

Abstract

HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are key drugs of highly active antiretroviral therapy (HAART) in the clinical management of AIDS/HIV-1 infection. Our recent studies showed that indolylarylsulfones (IASs) bearing a cyclic moiety at the 2-carboxamide nitrogen linked through a short spacer group were endowed with potent antiretroviral activity. Based on the results previously obtained, we aimed to expand the SAR studies by the introduction of new aryl or heteroaryl portions to the indole nucleus. Interestingly, for the first time IASs endowed with asymmetric centre have shown significant differences in term of antiretroviral potency. In particular, the R-enantiomer proved to be exceptionally potent and uniformly superior to the S-enantiomer against the whole viral panel. Docking studies showed that the methyl group of the R-enantiomer (Figure 1) pointed toward the cleft created by the K103N mutation, differently from the corresponding group of (S) counterpart. By calculating the solvent accessible surface, we observed that the exposed area of the RT in complex with S-enantiomer was larger than the area of the (R) complex
Inglese
Program and Abstracts, 30th International Conference on Antiviral Research
30th International Conference on Antiviral Research
Atlanta, GA, USA
21-mag-2017
25-mag-2017
N/A
N/A
Famiglini, V., La Regina, G., Coluccia, A., Masci, D., Roger, B., José A., E., Emmanuele, C., Giovanni, M., Drug design and synthesis of new indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors, Abstract de <<30th International Conference on Antiviral Research>>, (Atlanta, GA, USA, 21-25 May 2017 ), N/A, Atlanta (Georgia), USA 2017:2017 87-87 [http://hdl.handle.net/10807/195406]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/195406
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact